Belvedere Trading
BBIO icon

Belvedere Trading’s BridgeBio Pharma BBIO Stock Holding History

Belvedere Trading’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-21,600
Closed -$593K – 708
2024
Q4 		$593K Buy
21,600
+7,700
+55% +$199K ﹤0.01% 222
2024
Q3 		$354K Sell
13,900
-17,300
-55% -$454K ﹤0.01% 237
2024
Q2 		$790K Buy
31,200
+21,800
+232% +$596K ﹤0.01% 132
2024
Q1 		$291K Sell
9,400
-8,500
-47% -$289K ﹤0.01% 248
2023
Q4 		$723K Buy
17,900
+2,600
+17% +$78.1K ﹤0.01% 121
2023
Q3 		$403K Sell
15,300
-20,500
-57% -$582K ﹤0.01% 138
2023
Q2 		$616K Buy
35,800
+4,900
+16% +$73.7K ﹤0.01% 113
2023
Q1 		$512K Buy
+30,900
New +$360K ﹤0.01% 143
2022
Q3 		– Sell
-8,300
Closed -$80K – 277
2022
Q2 		$80K Buy
+8,300
New +$69.4K ﹤0.01% 264
2022
Q1 		– Sell
-15,200
Closed -$157K – 474
2021
Q4 		$157K Buy
+15,200
New +$643K 0.01% 239

Other funds holding BBIO

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Belvedere Trading's BBIO Position: Q1 2025 in Review

Belvedere Trading sold out of BridgeBio Pharma (BBIO) in Q1 2025, closing a stake of 11,316 shares — an estimated $311K sold.

Belvedere Trading first reported a position in BBIO in Q4 2021 and held it in 9 quarters. The position peaked at $1.09M in Q4 2023. 304 funds tracked by Wall St. Rank hold BBIO as of Q1 2025.

  • Belvedere Trading reported no remaining BridgeBio Pharma position as of Q1 2025 after selling out during the quarter.
  • Belvedere Trading sold 11,316 BridgeBio Pharma shares in Q1 2025, an estimated $311K.
  • Belvedere Trading first reported a position in BridgeBio Pharma in Q4 2021 and held it in 9 quarters.
  • Belvedere Trading's BridgeBio Pharma position peaked at $1.09M in Q4 2023.
  • 304 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2025.

Based on Belvedere Trading's 13F filing for Q1 2025, filed 9 May 2025.